Evaluation of intravenous voriconazole in patients with compromised renal function
© Lilly et al.; licensee BioMed Central Ltd. 2013
Received: 24 March 2012
Accepted: 8 January 2013
Published: 16 January 2013
Skip to main content
© Lilly et al.; licensee BioMed Central Ltd. 2013
Received: 24 March 2012
Accepted: 8 January 2013
Published: 16 January 2013
Incorporation of the solubilizing excipient, sulfobutylether-β-cyclodextrin (SBECD), in the intravenous (IV) formulation of voriconazole has resulted in the recommendation that this formulation be used with caution in patients with creatinine clearances (Clcr) < 50 mL/min. This study evaluated the safety of IV voriconazole compared with two other IV antifungals not containing SBECD in patients with compromised renal function.
A total of 128 patients aged 11–93 years who had a baseline Clcr < 50 mL/min between January 1, 2007 and December 31, 2010 were identified from a database of a university-affiliated inpatient healthcare system; of these, 55 patients received caspofungin, 54 patients received fluconazole, and 19 patients received voriconazole. Changes in serum creatinine (Scr) and Clcr levels while on therapy were compared with baseline values and between groups.
The groups had similar characteristics apart from the larger proportion of females that received fluconazole. Baseline Scr was higher in those receiving caspofungin, but maximal increases of Scr and decreases in Clcr were greatest for the fluconazole group. Acute kidney injury (AKI), assessed by RIFLE criteria, was more frequent in the fluconazole vs. the caspofungin group (p < 0.01); incidence of AKI in the voriconazole group was not significantly different than found in the other two groups. The infecting organism was a predictor of AKI and formulation with SBECD was not.
Treatment of fungal infections in patients with compromised renal function with an SBECD-containing antifungal agent was not associated with AKI in clinical practice. Since the infecting organism was associated with AKI, decision on which antifungal to use should be determined by susceptibilities to the organism and not the incorporation of SBECD in the IV formulation.
The incidence of serious fungal infections has increased over the last two decades , coincident with increased prevalence of immunocompromised patients, including those treated for cancer, acquired immune deficiency syndrome (AIDS), and those treated with immunosuppressants in the setting of organ transplantation and autoimmune disease. Historically, yeasts were the most prevalent cause of fungal infections with Candida albicans being the most frequently identified. More recently, yeast infections have declined following the introduction and wide spread use of fluconazole and lipid-based amphotericin-B formulations. Further, there has been a shift in the frequency of isolates from C. albicans to non-albicans species, most notably C. glabrata and C. parapsilosis[2, 3]. This decline in Candidal infections was associated with a rise in mould infections including aspergillosis . More recently, the incidence of Aspergillus infections has been stable, [5, 6]. However, a rising incidence of nosocomial infections by other filamentous fungi has been observed. These previously ultra-rare fungal diseases, such as Scedosporium spp., Fusarium spp., and Zygomycetes spp., are becoming more prevalent, particularly in immunocompromised patients in tertiary care cancer centers [7, 8].
The increase in the availability of agents that are available to treat fungal infections allows individual agents to be selected based on the sensitivity of the organism and the potential toxicity profile of the antifungal agent. The high incidence of renal failure associated with the administration of polyenes has led to sensitivity regarding adverse renal effects of antifungal agents. Nephrotoxicity associated with the administration of first generation β-cyclodextrins  led to warnings and restrictions that have made it difficult to study the nephrotoxicity of later generation cyclodextrins. SBECD is a second-generation cyclodextrin chemically-engineered not to accumulate in renal epithelial cells and thus avoid acute kidney injury. Despite limited evidence that SBECD has not been associated with renal impairment [10, 11], restrictions in its use in patients with estimated creatinine clearances (Clcr) less than or equal to 50 mL/min have been documented .
Our study is designed to test the hypothesis that treatment of a known or suspected fungal infection that is serious enough to warrant the use of an intravenous agent in patients with impaired renal function at the start of therapy with an SBECD-containing antifungal is associated with a higher frequency of renal dysfunction than treatment with a non-SBECD containing antifungal. To date, there have been no comprehensive evaluations incorporating large population sizes of clinical populations in the literature. We found in our study that the inclusion of SBECD was not associated with drug-associated kidney injury in acutely-ill patients with systemic fungal infections.
p-value for overall difference
Age, Mean (SD)
Male, n (%)
White, n (%)
Length of treatment (days)
Comorbidities: Diabetes mellitus, hypertension or nephropathy, n (%)
Underlying condition, n (%)
More than 1 underlying condition
Concomitant nephrotoxic agent, n (%)
Underlying fungal disease, n (%)*
Indication for antifungal therapy, n (%) †
Presumed or Confirmed
The underlying conditions are also listed in Table 1. More than half of the patients were being treated in the intensive care unit. Seventy-five percent of all patients had presumed or confirmed fungal disease, as determined by an Infectious Diseases consultant (9 [47%], 46 [84%], and 42 [78%] patients administered voriconazole, caspofungin, and fluconazole, respectively, NS; Table 1).
Renal function at the start of therapy
p-value for overall difference
Baseline Scr (mg/dL)
Baseline BUN (mg/dL)
Baseline Clcr (mL/min)
Differences in renal function during therapy
Baseline Clcr (mL/min)
Maximum ↑ Scr, mg/dL (SD)
Lowest Clcr during treatment, mL/min (SD)
Clcr at EOT, mL/min (SD)
% Change Clcr (Lowest-SOT)/SOT (SD)
Renal dysfunction, n (%)
The differences in 28-day mortality among the three treatment groups were not statistically significant. Mortality of patients in the voriconazole, caspofungin, and fluconazole treatment groups was 42.1%, 29.1%, and 25.9% respectively (p = 0.44).
Stepwise logistic regression analyses were performed using the following 7 independent variables: age, race, comorbidities, concomitant treatment with a nephrotoxic agent, the presence or absence of SBECD, and site of infection which was recoded into 3 groups (abdominal + lung, systemic, and urine + wound). The coefficient for infecting organism had a Wald statistic equal to 3.90 and a p-value of 0.048. Thus, this model identified the infecting organism as the only significant predictor of renal dysfunction by the RIFLE criteria.
This study found no evidence of renal toxicity that was attributable to the solubilizing agent, sulfobutylether-β-cyclodextrin (SBECD), in patients with impaired renal function (Clcr < 50 mL/min) who were treated with an intravenous antifungal agent in clinical practice. The maximal increase in Scr levels was less and calculated nadir Clcr was higher for the SBECD-containing voriconazole group than those of fluconazole and caspofungin groups that did not contain SBECD. Importantly, SBECD was not associated with increased renal dysfunction during or at the end of therapy.
Voriconazole, a second-generation triazole, is a steric inhibitor of fungal cytochrome P450-dependent 14α-sterol demethylase, which is essential for the conversion of lanosterol to ergosterol required for building the cell membranes of fungal organisms . Like other triazoles, voriconazole has activity for this enzyme for both yeast and moulds, whereas fluconazole, the backbone structure of voriconazole, is only active against yeast. The early development plan for voriconazole incorporated the medical need for an intravenous formulation [written communication, Chris Hitchcock, PhD, Pfizer Inc]. Since voriconazole has a low aqueous solubility (0.7 mg/mL) , its intravenous formulation includes SBECD as a solubilizing agent.
Naturally occurring cyclodextrins, notably α- and β-cyclodextrins, are reabsorbed and concentrated in the renal tubule, resulting in acute kidney injury at clinically-translatable doses in animal models . SBECD is a rationally-designed cyclodextrin which does not undergo significant tubular reabsorption, thus it was formulated to prevent injury to renal tubular cells. Animal studies with SBECD have not shown discrete changes in renal morphology at doses used clinically ; moreover, SBECD is not nephrotoxic in these models when given at dose equivalents of naturally occurring cyclodextrins that are associated with nephrotoxicity and/or hepatotoxicity. However, at the time of FDA approval, a lack of information regarding the safety of SBECD in patients with impaired renal function led to warnings against the use of SBECD in patients with Clcr < 50 mL/min for products including intravenous voriconazole . This study is important to clinicians because it provides evidence that SBECD-containing medications can be used to treat patients with serious fungal infections including those with impaired renal function without increased risk of nephrotoxicity.
Our main finding that treatment of a serious fungal infection for patients with impaired renal function with SBECD-containing voriconazole is not associated with worse renal outcomes than treatment with a non-SBECD containing alternative antifungal is consistent with recent smaller studies. A retrospective analysis of the Candida Phase 3 trial database for nephrotoxic effects of intravenous voriconazole containing SBECD did not detect renal toxicity from voriconazole in contrast to the renal dysfunction associated with amphotericin B [10, 15]. Despite accumulation of SBECD in the plasma of patients with compromised renal function [16–18], its lack of reabsorption in renal epithelial cells appears to prevent deleterious effects on renal function in this and other clinical reports [19–21].
Targeting high risk patients may have increased the ability of our study of modest size to detect differences among agents with regard to renal toxicity. The association of fluconazole with worse renal function during therapy is consistent with its labeling: “In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain .” Our findings do not identify fluconazole as a direct nephrotoxin, rather they imply that the underlying disease state of which fluconazole is treating influences renal function. This is consistent with our identification of the organism as a significant predictor of renal outcome. The association was driven by worse renal function among those with systemic fungal infections, many of whom were treated with fluconazole for sensitive isolates of Candida albicans. It is important to note that all cases of renal impairment were classified as mild-to-moderate according to the RIFLE criteria . We did not find evidence for other possible mechanisms of renal toxicity such as obstructive hydronephrosis [24–31] or microangiopathy such as that which occurs with hemolytic uremic syndrome [32, 33].
This study has important limitations that should be taken into account when interpreting the data. It is a nonrandomized observational study of clinical practice at an academic medical center with policies that mandate the involvement of infectious disease experts for cases involving the administration of intravenous antifungals for nearly all patients. This leads to differences among the groups that are due to non-random factors that may be important. On the other hand, this approach may be more informative about the effects in clinical practice because cases are not excluded. We attempted to review patient cases with compromised renal function treated with amphotericin B but, despite our large database, we could not find a sufficient number of patients meeting this criteria. Similarly, the number of patients with compromised renal function treated with intravenous voriconazole is low and likely related to labeling that raises concerns about renal toxicity in this group.
Mortality was higher in the voriconazole group compared with the other two groups, likely as a result of the severity of the underlying fungal disease. A greater percentage of patients in the voriconazole group was infected with Aspergillus spp. A higher mortality rate is expected in this group because infection with Aspergillus spp. has been associated with higher mortality rates compared to yeast infections. In addition, a greater percentage of patients in the voriconazole group were treated with voriconazole prophylactically as part of a treatment plan for poor prognosis malignancies including acute myelogenous leukemia (AML). Importantly, differences among the indications for antifungal treatment did not appear to alter the validity of the association of the infecting organism that was isolated with the development of renal dysfunction. Nonetheless, there was a limited number of Candida and Aspergillus isolates identified in this study such that associations between the subspecies of yeast or mould with more severe renal disease could not be definitive.
Another limitation of this study is the lack of dosing information or therapeutic drug monitoring. At the time of data collection, there was no harmonization between pharmacy and medical records. However, there are defined guidelines for the dosing of the three IV antifungals established by the Food and Drug Administration which were reviewed by a UMass clinical pharmacist. Antifungal agent levels were not measured as part of this study and are not recommended by current therapeutic guidelines. The effects of SBECD on renal function that we observed do not suggest that measuring drug levels to prevent renal toxicity would be justified.
A main finding of this study is that the administration of SBECD in renally-compromised patients does not result in renal damage that is attributable to its inclusion in the formulation of voriconazole. The finding that the infecting organism is a significant predictor of renal outcomes in this high risk population suggests that the efficacy of the antifungal agent should be the dominant consideration when treating a serious fungal infection. Further studies are warranted to help us better understand the association between the underlying fungal infection and acute kidney injury.
We analyzed deidentified data from a large database of hospitalized patients from the UMass Memorial Healthcare System using the University of Massachusetts Biorepository database. All adults with documented or clinically suspected fungal infections that were treated with an intravenous antifungal therapy, specifically, voriconazole, fluconazole, or caspofungin, with baseline estimated Clcr < 50 mL/min, and who were hospitalized between 1/1/2007 and 12/31/2010 were identified. Those eligible for analysis had been dosed for a minimum of 4 days of IV antifungal therapy and had serum creatinine (Scr) levels while on therapy and at the end of IV antifungal therapy (EOT; ± 3 days). Patients were excluded from analyses if they had unstable renal function at baseline (assessed as a 50% difference in Scr or estimated Clcr on two measurements within 4 days prior to start of IV antifungal therapy). Patients undergoing chronic hemodialysis, hemofiltration, or other renal replacement therapies were excluded from study. All concomitant medications which could be considered nephrotoxic were evaluated in a blinded fashion (by DRL) and subsequently tabulated by treatment group (by VLW). The indication for treatment with an antifungal agent was classified as for prophylaxis, empiric treatment, or presumed/confirmed disease utilizing the EORTC guidelines .
This study was performed with the prior approval of the University of Massachusetts Human Subjects Committee under a waiver of the requirement for informed consent.
Changes in Scr levels and Clcr were evaluated during IV antifungal therapy. The highest Scr and lowest Clcr while on therapy and at EOT among the groups were compared with baseline Scr and Clcr, respectively, by F-test. We compared dichotomous variables with the Fisher’s exact test, and other categorical variables with the χ2 test. Continuous variables were compared using the F test or Wilcoxon rank-sum test and differences among groups with the log-rank test. Distributions of length of treatment were skewed, so these data are shown as median (IQR), and other data are shown as mean (SD). We assessed development of renal dysfunction with RIFLE scores  by linear test of trend. 2-sided p values < 0.05 were considered statistically significant.
Stepwise logistic regression was conducted with a p-value to enter and stay in the model set for p≤0.20. The dependent variable in the model was the presence of AKI. Prespecified potential independent variables included age, gender, body mass index, antifungal therapy, infecting organism, presence or absence of SBECD, site of infection, Clcr at baseline, presence or absence of concomitant potentially nephrotoxic agents, and comorbidities. For all analyses except the regression model, p < 0.05 was considered significant. Analyses were conducted using SAS Software version 9.2 (Cary, North Carolina, USA).
Actual body weight
Acquired immune deficiency syndrome
Acute kidney injury
Acute myelogenous leukemia
Blood urea nitrogen
End of therapy
Modification of diet in renal disease
Risk, injury, failure, loss of function, and end-stage renal disease
Start of therapy
This study was conducted by the University of Massachusetts Worcester and funded by Pfizer. Thomas Mayer, Joanne Meisner, Paul Ranauro, and Craig Lilly are employees of the University of Massachusetts Worcester who were paid consultants to Pfizer in connection with the development of this manuscript. These data were presented in part at the 49th Annual Meeting of the Infectious Diseases Society of America, Boston, Massachusetts, USA, October 20–23, 2011.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.